NCT03192046

Brief Summary

Parkinson disease (PD) is a progressive neurological disease that results in characteristic gait dysfunction. Gait problems include decreased velocity, decreased stride length, difficulty with initiation of gait, postural stability problems and alteration in joint kinematics.1 In this typically older patient population, these gait deviations affect their participation in household and community activities. The standard of care is currently focused on therapeutic exercise and cueing of various types (visual, auditory, verbal). Current interventions have not been demonstrated to markedly improve gait kinematics, so there is a need to identify interventions that could improve gait performance in this population. Lower extremity bracing is a common and well-established intervention for gait dysfunction with other populations, including stroke and brain injury. The braces allow for improved stability, sensory feedback, and consistent tactile cues to allow patients to have the best gait mechanics with each step. It is reasonable to hypothesize that appropriate bracing may have the potential to improve gait function and kinematics in PD since these patient often have gastroc-soleus weakness. Data from our early pilot studies indicates that bracing individuals with PD can positively impact their mobility. This includes improvements in velocity, step length, and dynamic balance. Additional data supported an upward trend in quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

June 13, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 19, 2017

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

March 23, 2022

Completed
Last Updated

March 23, 2022

Status Verified

February 1, 2022

Enrollment Period

4.3 years

First QC Date

June 13, 2017

Results QC Date

December 21, 2021

Last Update Submit

February 25, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Gait Capacity as Assessed b 6-Minute Walk Test

    The 6 Minute Walk Test (6MWT) is a test of walking (gait) endurance and walking velocity and measures the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The test will be used to determine participant's gait efficiency at baseline and at 6 months. While the total distance covered during six minutes (6MWTD) is often used as the standard measurement of gait capacity (i.e., the maximum distance one can achieve), the endurance (i.e., ability to maintain speed over a prolonged time) can be inferred by the gait speed trajectory (GST) during the 6MW test (6MWGST).

    Baseline and 6 months

Secondary Outcomes (2)

  • Change in Step Length

    Baseline and 6 months

  • Change in Temporal Spatial Gait Parameters Using the Computerized Gait Analysis System

    Baseline and 6 months

Study Arms (2)

Carbon Fiber Ankle Foot Orthosis (AFO)

EXPERIMENTAL

For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.

Device: Carbon Fiber Ankle Foot Orthosis (AFO)

Control Group, Walking Program Only

ACTIVE COMPARATOR

The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.

Other: Standardized walking/exercise program

Interventions

Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.

Carbon Fiber Ankle Foot Orthosis (AFO)

standardized walking/exercise program without any brace or AFO

Control Group, Walking Program Only

Eligibility Criteria

Age30 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Confirmed diagnosis of Parkinson's Disease according to the UK brain bank criteria.5
  • Age between 30 and 85.
  • Measurable decrement in gait velocity (between 35 and 15 percent below age-predicted norms for self-selected walking velocity) as measured by the 6 MWT
  • Hoehn and Yahr stage 2-3.
  • Less than 10 full heel raises in single limb stance bilaterally.

You may not qualify if:

  • Body mass index greater than 40.
  • Passive dorsiflexion range of motion less than approximately neutral (90 degrees)
  • Any other uncontrolled health condition for which gait training is contraindicated
  • Self-report of \> 1 fall/month
  • A score of 11 or less on the Short Orientation-Memory-Concentration Test of Cognitive Impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UT Southwestern

Dallas, Texas, 75235, United States

Location

MeSH Terms

Conditions

Gait Disorders, NeurologicParkinson Disease

Condition Hierarchy (Ancestors)

Neurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsParkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Results Point of Contact

Title
Staci Shearin
Organization
UtexasSouthwestern

Study Officials

  • Staci Shearin, Masters

    UT Southwestern

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a randomized, repeated measures, matched group study.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

June 13, 2017

First Posted

June 19, 2017

Study Start

September 1, 2016

Primary Completion

December 1, 2020

Study Completion

December 1, 2020

Last Updated

March 23, 2022

Results First Posted

March 23, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share

Locations